Back to the Future: Mismatched Unrelated Donor, Haploidentical Related Donor, or Unrelated Umbilical Cord Blood Transplantation?

Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.

Only 30% of patients who require an allogeneic hematopoietic cell transplant will have an HLA-matched sibling donor. A search for an unrelated donor will be undertaken for patients without a matched family donor. However, many patients, particularly patients of diverse racial and ethnic backgrounds, may not be able to rapidly identify a suitably matched unrelated donor. Three alternative graft ...

Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Hematopoietic cell transplantation (HCT) can be curative for selected malignant and nonmalignant diseases.1-13 However, utilization and success of HCT are limited by several obstacles, primarily related to the importance of donor-recipient genetic match for favorable outcomes. While in most settings, best results are offered by human leukocyte antigen (HLA)14,15–identical sibling transplantatio...

UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: MARROW OR UMBILICAL CORD BLOOD? Short title: Donor selection: Bone Marrow or Cord Blood?

Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia.

GT, a rare disorder of platelet function, can lead to life-threatening bleeding, particularly following the development of antiplatelet antibodies. Curative therapy includes HCT but previous reports are limited predominantly to matched siblings and have excluded CBT. Delayed or non-engraftment of platelets because of antiplatelet antibodies might be particularly concerning after CBT for GT. Her...

Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies.

PURPOSE OF REVIEW This review summarizes the state of the art of unrelated donor (URD) umbilical cord blood transplantation (UCBT) for the treatment of hematologic malignancies and discusses the current issues associated with the use of this hematopoietic stem cell (HSC) source. RECENT FINDINGS In contrast to the very high transplant-related mortality associated with the early experience of U...